Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
TWST is experiencing significant short-term selling pressure driven by institutional divestment and a technical correction following a period of rapid gains, despite positive long-term growth narratives.
Major institutional investors, including Wellington Management, have reduced their stakes in TWST, and significant insider selling has been reported over the past 90 days. These moves, combined with recent divestments by ARK Invest, are contributing to negative sentiment and increased selling pressure on the stock.
MarketBeatTWST shares have experienced a streak of consecutive daily losses, resulting in a significant pullback from recent highs. This technical weakness is attracting increased scrutiny regarding the company's path to profitability and high valuation relative to its persistent operating losses.
Trefis